Although, some studies which evaluated heterologous prime-boost COVID-19 vaccine of different platforms have reported higher frequency of spike-specific CD4+, CD8+ T-cells [4], strong and high titers of neutralising antibodies against B1.1.7 and B.1.351 strains [6,7]. This evidence concerns the gene CD4 and COVID-19.